Phio to present Phase 1b skin‑cancer trial data at SITC meeting
Phio Pharmaceuticals announced that it will share results from its Phase 1b trial of the INTASYL siRNA drug PH‑762 at the 41st Society for Immunotherapy of Cancer meeting in Phoenix. The company said the treatment was well‑tolerated and showed tumor‑shrinkage potential in cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. The CEO, Robert Bitterman, described PH‑762 as a possible tissue‑sparing neoadjuvant option. Phio intends to start a Phase 2b study during the first half of 2027.
Why it matters
The company’s press release indicates the data could position PH‑762 as a non‑surgical alternative for skin cancers, which may expand its market opportunity. Initiating a Phase 2b trial later this year will extend the development timeline and could affect future financing needs.
Key facts
- 1Phio will present Phase 1b trial results for PH‑762 at the SITC meeting on November 7, 2026. stocktitan.net
- 2The trial evaluated PH‑762 as a neoadjuvant intratumoral injection for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. investing.com
- 3Company officials said the treatment was well‑tolerated and may shrink tumors before surgery. stocktitan.net
- 4Robert Bitterman is President and Chief Executive Officer of Phio Pharmaceuticals. stocktitan.net
- 5John Strasswimmer, M.D., Ph.D., will deliver the presentation at 2:45 PM in Phoenix Convention Center. investing.com
- 6Phio plans to begin a Phase 2b trial in the first half of 2027. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.